DiaMedica Therapeutics Inc.
DMAC
Rank in Stocks
#11875
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical... DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Share Price
$9.65
Last synced: 2026-11-09
Market Cap
$520.38M
Change (1 day)
3.10%
Change (1 year)
52.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade DiaMedica Therapeutics Inc. (DMAC)
Category
Healthcare
Earnings for DiaMedica Therapeutics Inc. (DMAC)
Earnings in Jun 2026 TTM: $-37.51M
According to DiaMedica Therapeutics Inc.'s latest financial reports, its current earnings (TTM) are $-37.51M. In 2025 the company earned $-32.74M, a decrease compared to its 2024 earnings of $-24.41M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for DiaMedica Therapeutics Inc. from 2004 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-37.51M | 14.58% |
| 2025 | $-32.74M | 34.10% |
| 2024 | $-24.41M | 26.25% |
| 2023 | $-19.34M | 41.69% |
| 2022 | $-13.65M | 0.62% |
| 2021 | $-13.56M | 10.59% |
| 2020 | $-12.27M | 15.51% |
| 2019 | $-10.62M | 87.80% |
| 2018 | $-5.65M | 32.72% |
| 2017 | $-4.26M | 93.56% |
| 2016 | $-2.20M | 53.89% |
| 2015 | $-1.43M | -70.05% |
| 2014 | $-4.78M | -35.56% |
| 2013 | $-7.41M | -26.27% |
| 2012 | $-10.05M | 52.11% |
| 2011 | $-6.61M | 54.89% |
| 2010 | $-4.27M | 75.18% |
| 2009 | $-2.44M | 31.39% |
| 2008 | $-1.85M | -19.87% |
| 2007 | $-2.31M | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | $-192.73K | -66.20% |
| 2004 | $-570.16K | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -12,788.28% |
US
|
|
| $-2.73B | 7,175.20% |
US
|
|
| $-4.02B | 10,606.72% |
AU
|
|
| $2.83B | -7,633.32% |
BE
|
|
| $1.50B | -4,090.67% |
NL
|
Questions about DiaMedica Therapeutics Inc.'s net income
What is DiaMedica Therapeutics Inc.'s net income?
DiaMedica Therapeutics Inc.'s net income over the last twelve months is $-37.51M, as of Jun 2026.
What was DiaMedica Therapeutics Inc.'s net income in 2025?
In 2025, DiaMedica Therapeutics Inc.'s net income was $-32.74M, compared with $-24.41M in 2024.
How has DiaMedica Therapeutics Inc.'s net income changed since 2020?
From 2020 to 2025, DiaMedica Therapeutics Inc.'s net income was highest in 2020 ($-12.27M) and lowest in 2025 ($-32.74M).
How does DiaMedica Therapeutics Inc.'s net income compare with similar companies?
DiaMedica Therapeutics Inc.'s net income ($-37.51M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.